Clinical Trial Update: Japanese Phase 3 Study of Aflibercept in Neovascular Glaucoma Patients [Phase 3]

View source ↗

Summary

A Japanese Phase 3 trial of aflibercept in neovascular glaucoma has been completed with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glaucoma
• Neovascular Glaucoma

Drugs mentioned

• Aflibercept (Aflibercept)

Snippet

Sponsor: Bayer | Conditions: Glaucoma, Neovascular | Phase 3 | Status: COMPLETED | Results posted: 2017-07-21